Pfizer has commenced a new study analysing the co-administration of a booster dose of its Covid-19 vaccine followed by its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults aged 65 years and above.

All initial participants enrolled in the trial have been immunised with the vaccines, Pfizer noted.

Being developed in alliance with BioNTech, the Covid-19 vaccine received an emergency use authorization from the US Food and Drug Administration (FDA) for active immunisation to prevent Covid-19 in people aged 12 and older.

Pfizer is developing the 20vPnC candidate to prevent invasive disease and pneumonia due to 20 serotypes of Streptococcus pneumoniae in adults aged 18 and older.

The vaccine candidate contains capsular polysaccharide conjugates for the 13 serotypes in Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).

It also includes capsular polysaccharide conjugates for seven other serotypes that lead to pneumococcal disease and are linked to high case-fatality rates, antibiotic resistance, and/or meningitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In December 2020, the FDA agreed to a priority review of 20vPnC’s biologics licence application.

The European Medicines Agency also accepted to review the marketing authorisation application for the pneumococcal conjugate vaccine in adults in February.

Pfizer’s new trial will enrol 600 adult subjects from its Phase III Covid-19 vaccine trial.

These participants will have received the second dose of the vaccine a minimum of six months before moving into the latest combination study, Pfizer added.

The primary goal of the trial is the safety of co-administrating the vaccines, with a six-month follow-up after inoculation. Assessing immune responses generated by the vaccines will form the trial’s secondary goals.

A third dose of the Covid-19 vaccine will be administered to some participants as a booster dose.

Subjects in the trial will be given 20vPnC plus Covid-19 vaccine booster, 20vPnC plus placebo, or Covid-19 vaccine booster plus placebo.